Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Dec 15;35(Suppl 2):S113-S115.
doi: 10.1097/QAD.0000000000003081.

What we have learned from antiretroviral treatment optimization efforts over the last 5 years?

W D Francois Venter  1 , Celicia Serenata  1 , Marco Vitoria  2 , Luckyboy Mkhondwane  3 , Kenly Sikwese  4 , Toby Pepperrell  5 , Polly Clayden  6 , Ambar Qavi  7 , Meg Doherty  2 , Martina Penazzato  2 , Andrew Hill  8
Affiliations
Editorial

What we have learned from antiretroviral treatment optimization efforts over the last 5 years?

W D Francois Venter et al. AIDS. .

Abstract

Progression in the development of antiretroviral therapy has been remarkable, with new agents continuing to appear as options for modern regimens, including in low-and-middle income countries where the HIV epidemic is concentrated. Here, we reflect on progress made in guiding regimen changes to public health programmes, and the challenges facing selection of newer agents.

PubMed Disclaimer

References

    1. Vitoria M, Rangaraj A, Ford N, Doherty M. Current and future priorities for the development of optimal HIV drugs . Curr Opin HIV AIDS 2019; 14:143–149.
    1. Ford N, Ball A, Baggaley R, Vitoria M, Low-Beer D, Penazatto M, et al. The WHO public health approach to HIV treatment and care: looking back and looking ahead . Lancet Infect Dis 2018; 18:e76–e86.
    1. WHO Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach . Geneva: World Health Organization; 2013.
    1. Paton NI, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A, et al. EARNEST Trial Team. Assessment of second-line antiretroviral regimens for HIV therapy in Africa . N Engl J Med 2014; 371:234–247.
    1. Pepperrell T, Hill A, Moorhouse M, Clayden P, McCann K, Sokhela S, et al. Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic . J Virus Erad 2020; 6:70–73.

Publication types

MeSH terms

LinkOut - more resources